Trial Profile
An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Ligelizumab (Primary)
- Indications Urticaria
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 13 Nov 2021 Results published in the Allergy
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.
- 19 Jun 2019 This study has been completed in Spain and Greece (End Date: 02 May 2019), according to European Clinical Trials Database record.